Latex bead injection model useful for studying retinal ganglion cell loss

Article

A new model for latex bead injections demonstrates that this is a viable approach to increasing IOP and inducing loss of retinal ganglion cells in rats, said Rebecca M. Sappington, PhD, research fellow, Vanderbilt University, Vanderbilt Eye Institute, Nashville.

A new model for latex bead injections demonstrates that this is a viable approach to increasing IOP and inducing loss of retinal ganglion cells in rats, said Rebecca M. Sappington, PhD, research fellow, Vanderbilt University, Vanderbilt Eye Institute, Nashville.

Using a model adapted from earlier designs, Dr. Sappington and colleagues injected fluorescent latex beads 15 mm in diameter into the anterior chamber of one eye and saline into the other eye in a group of adult Norway Brown rats.

Investigators used a tonometer (Tono-Pen, Reichert Inc.) to measure IOP in awake rats and used the mean of 25 measurements to calculate changes over time. They also measured axonal area and loss of axons and performed histologic examinations. They were able to elevate IOP for up to at least 5 weeks by giving the rats two injections of beads; IOP levels increased by 30% to 40% over this period. A single injection reduced IOP about 30% over 2 weeks.

Investigators also observed that a 2.5-ml injection produced a slow rise in IOP, while a 5-ml injection produced a large initial increase. In addition, after 2 weeks of elevated IOP, eyes injected with the higher dose of latex beads showed a greater reduction in distal nerve retinal ganglion cells than in proximal nerve cells. In contrast, eyes that had been given the 5-ml injection of beads showed the same pattern of axon loss in the proximal and distal nerves, Dr. Sappington said. At 5 weeks, more severe axonal loss was again found in the distal nerve than in the proximal nerve in eyes that had received the smaller injection of beads. In eyes receiving the larger injection, the loss pattern remained consistent between the two types of nerves.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.